

REMARKS/ARGUMENTS

Claims 36-64 are active. In the Advisory Action dated March 30, 2010, Examiner Li declined to enter the previous after-final Amendment on the grounds that it would raise new issues that would require further consideration and/or search. The claims have been consolidated and represented as new claims 36-64 and find support in the original disclosure. No new matter has been added.

Objection

Claims 14-19, 21 and 23-30 were objected to, but not otherwise rejected.

Rejection—35 U.S.C. 103

Claims 10-13, 20 and 22-23 were rejected under 35 U.S.C. 103(a) as being anticipated by Hardy, et al., Virol. 217:252, and Kitamoto, et al., J. Clin. Micro. 40:2459. This rejection is moot. It would not apply to the new claims since the limitations of prior claims 14 and 15 appear in independent claim 36 which requires the combination of an immobilized anti-virus antibody and a labeled anti-virus antibody. Moreover, Hardy is directed to recombinant Norwalk Virus capsid protein and does not disclose the *Sapovirus* of claims 38 and 60-64. Therefore, this rejection does not apply to the present claims.

Conclusion

In view of the amendments and remarks above, the Applicants respectfully submit that this application is now in condition for allowance. An early notice to that effect is earnestly solicited.


Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)



Thomas M. Cunningham, Ph.D.
Registration No. 45,394